| System lacks accountability and evidence base, say health economists Related items from OnMedica Cancer Drugs Fund faces renewed barrage of criticism Plans to change next year’s National Tariff for NHS services face setback NICE’s cost-effectiveness system is harming patients, claim experts NHS cash pressures causing bad rationing decisions Cancer Drugs Fund axes 25 treatments from list |
Wednesday 29 April 2015
Pharmaceutical industry regulation undermines NICE drugs appraisal work
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment